AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation.
about
Modulatory effects of α7 nAChRs on the immune system and its relevance for CNS disordersTargeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational BiomarkerThe therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia.A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia.The current agonists and positive allosteric modulators of α7 nAChR for CNS indications in clinical trials.
P2860
AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
AQW051, a novel, potent and se ...... zation and phase I evaluation.
@ast
AQW051, a novel, potent and se ...... zation and phase I evaluation.
@en
type
label
AQW051, a novel, potent and se ...... zation and phase I evaluation.
@ast
AQW051, a novel, potent and se ...... zation and phase I evaluation.
@en
prefLabel
AQW051, a novel, potent and se ...... zation and phase I evaluation.
@ast
AQW051, a novel, potent and se ...... zation and phase I evaluation.
@en
P2093
P2860
P356
P1476
AQW051, a novel, potent and se ...... zation and phase I evaluation.
@en
P2093
Christopher R Pryce
Cristina Lopez Lopez
Dominik Feuerbach
Donald Johns
Frederique Chaperon
Graeme Bilbe
Kasra Shakeri-Nejad
Kevin McAllister
Klaus Kucher
Konstanze Hurth
P2860
P304
P356
10.1111/BPH.13001
P407
P50
P577
2015-01-12T00:00:00Z